Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, William J. Sandborn et al.|The Lancet|2017Cited by 198
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA studyWilliam J. Sandborn, Geert D’Haens, Fabio Cataldi et al.|Gut|2017Cited by 107
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Journal of Crohn s and Colitis|2021Cited by 34
Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA studyGeert D’Haens, W. Sandborn, S. Lee et al.|Unknown|2015Cited by 16
OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE studyWilliam J. Sandborn, Edward V. Loftus, Stefan Schreiber et al.|Journal of Crohn s and Colitis|2019Cited by 9